Physician profile
Sanjay Chatrath
NPI 1861591711
$13,517.28
in general payments reported to CMS, 2019-2025
52 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,302 · 2020: $1,370 · 2021: $2,657 · 2022: $1,982 · 2023: $1,749 · 2024: $1,802 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,205.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,672.94 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,201.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,140.45 | 2019-2025 | Viberzi, Linzess, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,103.32 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $986.57 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $760.64 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $640.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $616.04 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $514.10 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $501.73 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $463.26 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $405.89 | 2019-2022 | |
| Amarin Pharma, INC. | $352.07 | 2019-2021 | |
| Allergan, INC. | $321.93 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $308.78 | 2022-2025 | Rexulti |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Chatrath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.